Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s
Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlows applications include assessing the condition of blood vessels during and after surgery, determining proper placement of bypass grafts, and monitoring blood flow for implantable devices such as pacemakers, according to the Princeton, NJ-based firm. EchoCath will initially market EchoFlow to vascular surgeons for measuring blood-flow velocities but is also seeking corporate alliances for applications outside vascular surgery.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.